Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

Epizyme, a biopharmaceutical company, announced a conference call scheduled for March 1, 2022, at 8:30 a.m. ET to discuss its Q4 and full year 2021 financial results. The call will provide investors with a business update and can be accessed via phone or a live webcast. Epizyme focuses on developing novel epigenetic therapies aimed at revolutionizing cancer treatment. The company aims to deliver effective, patient-specific oral medicines that change standard-of-care.

Positive

• Scheduled call to discuss Q4 and full-year 2021 financial results, indicating transparency and engagement with investors.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update on Tuesday, March 1, 2022 at 8:30 a.m. ET.

To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 4082815. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call.

About Epizyme, Inc.

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer through novel epigenetic medicines. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take and based on a deep understanding of the patients that may benefit from them. The Company aspires to change the standard-of-care for patients and physicians by developing medicines with fundamentally new mechanisms of action. For more information, visit www.epizyme.com.

TAZVERIK® is a registered trademark of Epizyme, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005218/en/

Media:

Erin Graves

media@epizyme.com

(617) 500-0615

Investors:

Caitlin Stern

Real Chemistry

cstern@realchemistry.com

Source: Epizyme, Inc.

FAQ

When is Epizyme's conference call to discuss Q4 and full-year 2021 results?

Epizyme's conference call is scheduled for March 1, 2022, at 8:30 a.m. ET.

How can I participate in the Epizyme conference call?

Participants can join the conference call by dialing (877) 844-6886 for domestic calls or (970) 315-0315 for international calls, using conference ID 4082815.

What is the focus of Epizyme's business?

Epizyme is focused on developing novel epigenetic therapies targeted at specific cancer causes, delivering effective, patient-specific treatments.